Using Caris Life Sciences' database, researchers found that prostate and endometrial cancers with SPOP mutations have distinct immune characteristics.
The virtual clinic helped community oncologists interpret genomic testing results and led a third of cases to be enrolled in precision medicine drug trials.
In a prospective study, patients with an EGFR T790M somatic mutation at diagnosis had a 50 percent chance of having a germline mutation, suggesting the need for more specific guidelines.
Out of around 100 cases reviewed by subspecialists, most completed recommended, guideline-concordant germline and somatic testing, but many still did not.
Several of Pfizer's precision oncology products including Ibrance, Xalkori, and Braftovi saw declines in Q3.
Executives noted that its two recent acquisitions, Mirati Therapeutics and Turning Point Therapeutics, underscore its shift away from immunotherapy.
At ESMO, experts found the combination promising in KRAS G12C-mutated colorectal cancer patients, though some want more safety and overall survival data.
Experts at ESMO said the MARIPOSA studies support Rybrevant combinations as potential options for NSCLC, but survival data and patient stratification are needed.
Researchers presented data on new KRAS-targeted drugs and combinations from Revolution Medicines, Jacobio Pharma, Jiangsu HengRui Medicine, and InventisBio.
In a discussion of the ALINA trial results at ESMO, an expert suggested oncologists shouldn't stop offering adjuvant chemotherapy just yet.